NASDAQ$PLSE
Pulse Biosciences Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Pulse Biosciences reported financial results for Q2 2020.
Pulse Biosciences reported a net loss of $11.3 million for the second quarter of 2020. The company's cash, cash equivalents and investments totaled $37.8 million as of June 30, 2020, compared to $15.9 million as of March 31, 2020. The $30.0 million rights offering generated $29.5 million of net proceeds.
- Completed CellFX System GLP preclinical study treatments for FDA 510(k) submission.
- Conducted a formal Pre-Submission meeting with the FDA for CellFX System indication expansion.
- Submitted the CellFX System technical file to its European notified body in pursuit of the CE mark.
- Strengthened balance sheet with the completion of a substantially oversubscribed rights offering.
Headline financials
Revenue & EPS history
Pulse Biosciences · Revenue · Quarterly
$21K
Forward guidance
Pulse Biosciences' operations in the second quarter of 2020 experienced minimal impacts as a result of the COVID-19 pandemic. Product development and regulatory timelines have not been materially affected at this time but due to the uncertain scope and duration of the pandemic, we cannot reasonably estimate the future impact to our operations and financial results.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
-0.0%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+9.3%
Avg return
30 days after
49%
19 / 39 earnings
Positive
+33.9%
Q4 2022
Best reaction
-36.5%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.6% | -4.6% | +34.5% | |
| Q4 2025 | -14.4% | -23.4% | -11.9% | |
| Q3 2025 | -1.2% | -6.1% | -20.0% | |
| Q1 2025 | +1.4% | -3.3% | +1.5% | |
| Q4 2024 | +6.0% | +6.8% | +14.4% | |
| Q3 2024 | +2.3% | -10.9% | +25.6% | |
| Q2 2024 | +8.1% | +21.5% | +9.5% | |
| Q1 2024 | -10.7% | -3.6% | +88.2% | |
| Q4 2023 | -4.9% | -8.5% | -14.4% | |
| Q3 2023 | +12.8% | +18.6% | +95.5% | |
| Q2 2023 | -0.4% | +9.2% | -35.3% | |
| Q1 2023 | -2.5% | -4.6% | -16.0% | |
| Q4 2022 | +33.9% | +57.4% | +156.6% | |
| Q3 2022 | +10.9% | +12.5% | +57.1% | |
| Q2 2022 | +8.7% | +10.6% | +1.2% | |
| Q1 2022 | -36.5% | -7.7% | -3.9% | |
| Q4 2021 | -28.4% | -25.0% | -49.6% | |
| Q3 2021 | -0.2% | -1.5% | -21.4% | |
| Q2 2021 | +7.9% | -2.1% | +2.1% | |
| Q1 2021 | +4.8% | +1.7% | +3.6% | |
| Q4 2020 | -9.2% | -17.5% | -35.1% | |
| Q3 2020 | +15.9% | +22.3% | +40.5% | |
| Q2 2020 | -6.4% | -6.1% | -15.0% | |
| Q1 2020 | +18.8% | -1.7% | -27.2% | |
| Q4 2019 | +21.1% | +5.2% | +14.6% | |
| Q3 2019 | -3.5% | -2.8% | -1.7% | |
| Q2 2019 | -2.5% | +4.6% | +16.1% | |
| Q1 2019 | -32.5% | -22.1% | -26.8% | |
| Q4 2018 | +4.0% | +11.3% | +9.4% | |
| Q3 2018 | +22.7% | +32.7% | +17.3% | |
| Q2 2018 | -0.9% | -6.7% | +4.1% | |
| Q1 2018 | -14.7% | -25.1% | -12.4% | |
| Q4 2017 | +0.1% | +1.8% | +38.5% | |
| Q3 2017 | +9.1% | +18.0% | -11.0% | |
| Q2 2017 | -16.6% | -11.6% | -25.2% | |
| Q1 2017 | -9.5% | -14.7% | +24.9% | |
| Q4 2016 | +6.4% | +18.7% | +12.7% | |
| Q3 2016 | +0.0% | -0.7% | -10.6% | |
| Q2 2016 | +1.5% | +2.2% | +31.3% | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro